PhRMA Statement on House Tri-Committee Health Reform Bill

Washington, D.C. (July 14, 2009) — Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Ken Johnson issued the following statement about the House Tri-Committee health care reform bill:

The Value of Investment in Healthcare Executive Summary

The Biopharmaceutical Sector's Impact on the Economy of the U.S.

White House Healthcare Summit in Vermont Offers Opportunity for Input into Reform

Washington, D.C. (March 17, 2009) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO Billy Tauzin today released the following statement regarding the White House health reform summit in Burlington, Vermont today:

White House Healthcare Summit Offers Opportunity for Input into Reform

Washington, D.C. (March 12, 2009) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO Billy Tauzin today released the following statement regarding the White House health reform summit in Dearborn, Michigan today:

PhRMA Statement on the President’s FY 2010 Budget Proposal

Washington, D.C. (February 26, 2009) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO Billy Tauzin today released the following statement regarding President Obama’s fiscal year 2010 budget:

Prescription Medicines Account for Only One-Tenth of Every Health Care Dollar

The use of prescription medicine is growing because they play an increasingly central role in treatment under clinical guidelines, and because earlier and preventive treatments are becoming more common. Nonetheless, while use of prescription medicines as the first, best therapy to prevent or treat a disease grows, prescription medicines continue to comprise only a small portion of health care spending in the United States.

Prescription Drug Price Trends Are In Line with Medical Inflation

Pages

Subscribe to RSS - Value